valdecoxib has been researched along with Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Casini, A; Lehtonen, JM; Parkkila, S; Scozzafava, A; Supuran, CT; Vullo, D | 1 |
| Innocenti, A; Knaus, EE; Scozzafava, A; Supuran, CT | 1 |
| Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L | 1 |
| Cheng, C; Jia, Y; Jin, X; Liu, Y; Wang, G; Yao, L; Zhang, J; Zhou, F | 1 |
| Bartzatt, R | 1 |
| Vanchieri, C | 1 |
1 review(s) available for valdecoxib and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction | 2015 |
5 other study(ies) available for valdecoxib and Neoplasms
| Article | Year |
|---|---|
Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII with aromatic and heterocyclic sulfonamides: a novel target for the drug design.
Topics: Amino Acid Sequence; Animals; Carbonic Anhydrase Inhibitors; Cytosol; Drug Design; Humans; Hydrogen-Ion Concentration; Isoenzymes; Kinetics; Molecular Sequence Data; Neoplasms; Rats; Structure-Activity Relationship; Sulfonamides | 2004 |
Phenylethynylbenzenesulfonamide regioisomers strongly and selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic isoforms I and II.
Topics: Antigens, Neoplasm; Carbonic Anhydrase I; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Carbonic Anhydrases; Cytosol; Drug Screening Assays, Antitumor; Humans; Isoenzymes; Molecular Targeted Therapy; Neoplasms; Stereoisomerism; Structure-Activity Relationship; Sulfonamides | 2011 |
Simultaneous determination of parecoxib and its main metabolites valdecoxib and hydroxylated valdecoxib in mouse plasma with a sensitive LC-MS/MS method to elucidate the decreased drug metabolism of tumor bearing mice.
Topics: Animals; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cyclooxygenase 2 Inhibitors; Cytochrome P-450 Enzyme System; Drug Monitoring; Female; Humans; Isoxazoles; Mice; Mice, Inbred BALB C; Neoplasms; Oxazoles; Prodrugs; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Sulfonamides; Tandem Mass Spectrometry; Xenograft Model Antitumor Assays | 2018 |
Drug analogs of COX-2 selective inhibitors lumiracoxib and valdecoxib derived from in silico search and optimization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Computer Simulation; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Design; Humans; Isoxazoles; Models, Molecular; Neoplasms; Pain; Sulfonamides | 2014 |
Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Incidence; Isoxazoles; Lactones; Membrane Proteins; Meta-Analysis as Topic; Myocardial Infarction; Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration | 2005 |